Will Compounded Semaglutide Be Banned in the US?

The compounded version of semaglutide has grown in popularity, particularly in the weight loss market. Some clinics offer the compounded version at a lower cost than the branded drugs, while others promote its use as a more flexible and customizable option for patients who may not respond well to standard dosages.

However, this increase in demand for compounded semaglutide has raised concerns about its safety, quality control, and the regulatory framework that governs its use. This has sparked discussions about whether compounded semaglutide could face regulatory scrutiny or even be banned.

To understand this, it is essential to consider the scientific, regulatory, and ethical factors involved. This article explores the current status of compounded semaglutide, its safety and efficacy, and the likelihood of it being banned.

Is Compounded Semaglutide Safe?

Compounding may be legal, but the safety of compounded semaglutide is not guaranteed. Unlike FDA-approved drugs like Ozempic, Wegovy, and Rybelsus, compounded semaglutide hasn’t undergone the rigorous testing required to ensure its safety, effectiveness, and quality. Without large-scale clinical trials or FDA oversight, there’s a risk that compounded versions may not meet the same high standards as their approved counterparts.

Some compounded semaglutide products use salt forms of the drug, such as semaglutide sodium or semaglutide acetate, which differ from the active ingredient in FDA-approved products.

According to the FDA, there’s no evidence that these salts are as safe or effective, and they aren’t legally recognized for use in compounding. Even Novo Nordisk, the manufacturer of FDA-approved semaglutide, has stated that compounded versions are not equivalent to authentic medications.

Does Compounded Semaglutide Work?

Compounded semaglutide may not work as well as FDA-approved semaglutide and may pose a higher risk to patients, including:

1. Impurities

A recent study found that follow-on and compounded versions of semaglutide may contain impurities not found in the original drugs. These impurities can arise from differences in manufacturing processes and include:

• • High molecular weight proteins
  • Trace metals
  • Anions and counterions
  • Residual solvents

These substances not only compromise safety but also indicate inconsistent manufacturing quality, raising concerns about their reliability.

Back in 2023, Novo Nordisk took legal action against two Florida-based compounding pharmacies. These pharmacies allegedly sold drugs marketed as containing semaglutide that were impure and “potentially unsafe.” Testing revealed that one product contained 33% unidentified impurities.

2. Increased Risk of Immune Reactions

The study also found “neoepitopes” in the products. These are protein fragments that the body’s immune system may see as foreign. This means there’s a higher chance that the body might react to the medication. This could lead to:

• • Allergic reactions (e.g., rash, swelling, or hives)
  • More serious immune responses, such as inflammation or fever

In some cases, the immune system could neutralize the drug’s effects, reducing its effectiveness for weight loss or blood sugar control.

3. Reduced Effectiveness and Bioavailability

Compounded versions of the semaglutide tablet, Rybelsus, also exist. Among the 8 oral semaglutide products tested in the study, several had less semaglutide than what was claimed on their labels.

The study also found differences in how the semaglutide and its carrier compound, SNAC, were released during digestion. Variations in release could mean that the medication doesn’t dissolve properly or isn’t absorbed consistently.

These differences can reduce bioavailability, which is the amount of drug that enters the bloodstream and is available to do its job. Lower bioavailability means the medication may not work as well.

4. Administration Errors

The FDA has received multiple reports of severe adverse events, some requiring hospitalization, due to dosing errors with compounded injectable semaglutide. These errors included patients accidentally injecting five to 20 times the intended dose because they were unfamiliar with syringe measurements.

Some healthcare providers also miscalculated doses during conversions, leading to overdoses. For instance, a provider prescribed 25 units instead of 5 units, causing severe vomiting in a patient. In another case, three patients received 10 times the intended dose due to a miscalculated prescription, resulting in nausea and vomiting.

Report Adverse Events to the FDA!

If you experience adverse events or medication errors with compounded semaglutide products, the FDA encourages you to report them through the MedWatch Adverse Event Reporting Program. Here’s how you can help ensure safety and accountability:

1. Visit MedWatch: The FDA Safety Information and Adverse Event Reporting Program to complete and submit your report.
2. Submit by Fax: Download the MedWatch form, fill it out, and send it via fax to 1-800-FDA-0178.

Your report helps improve drug safety for everyone!

Will Compounded Semaglutide Be Banned?

As of January 2025, compounded semaglutide has not been officially banned in the United States. However, significant developments indicate a move toward stricter regulation due to safety concerns.

Novo Nordisk has formally requested the FDA to prohibit compounding pharmacies from producing their own versions of semaglutide. This request is based on concerns regarding the drug’s complex formulation and reports of adverse events linked to compounded versions.

Eli Lilly, which produces tirzepatide (marketed as Mounjaro and Zepbound), has raised similar concerns. The company has taken legal action against compounders and telehealth startups accused of producing untested, unauthorized versions of its medications. These actions highlight the broader industry concern about patient safety and the regulatory gaps in compounded medications.

The FDA is currently reviewing these petitions but has yet to make a final decision on banning compounded semaglutide. Meanwhile, patients and healthcare providers are advised to exercise caution when considering compounded versions of these medications, given the potential risks and the absence of FDA approval for these formulations.

What About Tirzepatide?

The resolution of the tirzepatide shortage in December 2024 has prompted the FDA to enforce compounding restrictions for this drug. Under FDA regulations, compounded versions of commercially available medications are only permitted during an active shortage.

To minimize disruption for patients currently receiving compounded tirzepatide, the FDA is allowing a transition period before enforcing regulations:

• • State-Licensed Pharmacies (Section 503A): These pharmacies are permitted to continue compounding, distributing, or dispensing tirzepatide injections until February 18, 2025 (60 days from the announcement).

• • Outsourcing Facilities (Section 503B): These larger facilities are allowed to continue similar activities until March 19, 2025 (90 days from the announcement).

In contrast, semaglutide remains on the FDA’s drug shortage list. As a result, compounding pharmacies can continue producing compounded semaglutide until the shortage is formally resolved.

Ethical Concerns Around Compounded Semaglutide

The use of compounded semaglutide raises significant ethical concerns, particularly regarding transparency, patient safety, and potential misuse. Many websites selling compounded versions of popular weight-loss drugs, such as those from Novo Nordisk and Eli Lilly, fail to provide accurate or complete information about their products.

A study of 79 websites revealed that over half failed to disclose that their compounded products lack FDA approval. This may lead consumers to believe these drugs meet the same safety and efficacy standards as approved medications. Additionally, 37% of websites implied FDA approval through misleading language or visuals, such as displaying the FDA logo.

Transparency issues extend further. Some websites failed to disclose that they were selling compounded products, and about 40% of websites overstated the benefits of compounded semaglutide. Moreover, nearly half failed to provide adequate information on side effects or precautions.

Another concern is the potential for misuse. As compounded semaglutide is often marketed as a weight-loss solution, it may be used by individuals without a genuine medical need, increasing the risk of abuse. This raises ethical questions about whether compounding pharmacies and clinics should promote semaglutide in this way, given the lack of regulation and oversight for these products.

The Future of Compounded Semaglutide

The FDA has already begun tightening regulations around compounded medications in general. Incidents involving poorly compounded medications, including reports of dosing errors and contamination, may push the FDA to introduce stricter guidelines further.

If these issues persist and are deemed a significant public health risk, the agency could even consider banning compounded versions of semaglutide altogether.

At the same time, supporters of compounded semaglutide argue that it serves as a critical alternative for patients who cannot access or afford FDA-approved versions of the drug. Compounding offers flexibility to tailor medications to individual patient needs, such as adjusting doses or formulations for better outcomes.

However, for compounded semaglutide to remain an option, the compounding industry must adhere to rigorous quality control standards and ethical practices. Without consistent safeguards, the risk of heightened regulation or outright bans remains significant.

Looking Forward

While compounded semaglutide has not been banned yet, it faces significant regulatory, legal, and ethical challenges. If compounded semaglutide continues to be marketed without proper regulations or clinical evidence, it could eventually face a ban or stricter oversight.

Until then, patients seeking semaglutide for weight loss or diabetes management should carefully consider the potential risks and benefits and consult a healthcare professional to ensure they receive the best possible treatment.

Frequently Asked Questions